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Introduction
The capacity of antitumor T-cell responses to be curative in cancer patients is known from clinical studies of adoptive cell therapy, but the induction of potent endogenous T-cell responses through therapeutic vaccination remains a challenge (1, 2) . Trials where patients received personalized vaccines targeting predicted neoantigens have generated significant enthusiasm in the field because they demonstrate the feasibility of immunizing against antigens that should not be restrained by tolerance (3, 4) . Yet, the immunogenicity of the vaccines reported in these trials remain modest. For example, Ott et al. employed "long" neoantigen-containing peptides as immunogens, which are attractive due to their defined nature, relative ease of manufacturing, favorable safety profile, and requirement of professional antigen presenting cells (APCs) for presentation (5) . However, as observed in many other peptide vaccine trials, CD8 + Tcell responses were only detectable after extended peptide stimulation ex vivo (4) . Much room remains for improvement in the immunogenicity of these vaccines.
To generate more potent peptide vaccines, a variety of approaches based on optimized formulation and immunization regimens have been demonstrated. Vaccine responses have been boosted by the utilization of altered peptide ligands, or high-affinity, non-self epitopes that prime cross-reactive T-cell responses against tumor antigens (6) . Significant effort has been put into developing adjuvants to enhance T-cell responses following peptide vaccination, including the use of TLR agonists (7), type I interferons (8) , and T reg -disrupting monoclonal antibodies (7, 9) .
Vaccine formulation can also contribute to the persistence and quality of antitumor immunity.
One of the most common emulsion formulations, incomplete Freund's adjuvant, has been found to depot peptide antigens at the injection site and sequester T cells distal from the tumor, which 4 may harm antitumor immunity, whereas formulations that are non-persisting at the site of vaccination may prove to be more effective (10) .
The poor lymphatic drainage and short in vivo half-life of linear peptides likely contribute to the low potency of peptide vaccines (11) (12) (13) (14) . We previously reported that enhanced lymph node (LN)-targeting of peptides can be achieved by covalently modifying peptides and molecular adjuvants with diacyl lipids, with the peptides linked through a PEG spacer, and this trafficking enhancement results in a corresponding increase in T-cell priming (14). The mechanism of action is thought to involve binding of the lipid tails to endogenous albumin, allowing peptides and molecular adjuvants to "hitchhike" on albumin to the draining LN, similar to the mechanism of action of sentinel LN mapping dyes in clinical use (15, 16) .
Here, we explored in detail mechanisms of action of these molecular vaccines and evaluated the role of distinct components of the amphiphile (amph)-vaccine platform. We tested the relative efficacy of several different albumin-binding moieties, the stability of amph-vaccine conjugates in presence of serum proteases, the effect of employing different adjuvants with amph-peptides, and the importance of the neonatal Fc receptor and cross-presenting dendritic cells (DCs) in amph-vaccine immunogenicity. We also assessed the duration and location of antigen presentation following amph-vaccine administration in vivo. Together, our data support the use of albumin-binding as a general design criterion for improving peptide vaccines by improving stability and lymphatic distribution, resulting in enhanced and prolonged antigen presentation in the LNs for superior CD8 + T-cell priming. were carried out as previously described (14) . Synthesis of the Vitamin E-CpG conjugate was performed as described in (14) using α-Tocopherol-TEG Phosphoramidite (Glen Research) with the following changes: after conjugation in solid phage, cleavage and ultra-mild deprotection was performed using 3:1 tertbutylamine in water for 6 hours at 65°C and the 5' dimethoxytrityl (DMT) group was removed using 80% acetic acid at room temperature for 2 hours, followed by an ethanol precipitation. Following cleavage and deprotection, oligos were purified via RP-HPLC and quantified using UV-VIS. For synthesis of TAMRA-labeled Vit. ECpG, a 3' TAMRA bead was utilized (TAMRA lcaa CPG 500Å, ChemGenes), followed by the ultra-mild cleavage and deprotection conditions described above. Synthesis of Vitamin B3 CpG was performed using 5'-Niacin-CE Phosphoramidite (Link Technologies). All CpG oligonucleotide conjugates used an ODN class B sequence 1826 with two guanine spacers.
Materials and Methods

Oligo conjugate synthesis
on
Synthesis of DSPE-PEG-EGP constructs
Reaction partners and conjugate structures are shown in Supplementary Fig. S1 . The peptide antigen was first synthesized using 9-fluorenyl methoxycarbonyl (Fmoc) solid-phase peptide synthesis with pre-loaded Wang resin (EMD Millipore). Synthesis was performed on a CEM Liberty Blue automated microwave peptide synthesizer. Coupling reactions were performed using 4 eq. of Fmoc-protected amino acid, 4 eq. of N,N'-diisopropylcarbodiimide (DIC)) and 8 eq. of ethyl(hydroxyimino)cyanoacetate (Oxyma pure) and removal of Fmoc groups on resin-attached amino acids was achieved with 20% 4-methylpiperidine in DMF. After synthesis, peptides were cleaved off the resin in a 95:2.5:2.5 trifluoroacetic acid (TFA)/triisopropylsilane (TIPS)/H 2 O mixture for 3 hours and washed with dichloromethane.
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Rotary evaporation and precipitation in cold diethyl ether yielded the crude product. Crude peptides were purified by HPLC (Waters Prep 150) on a C18 Phenomenex Kinetex column in a water-acetonitrile gradient containing 0.1% v/v TFA. Pure fractions were collected and identified using ESI-MS. The combined fractions were subjected to rotary evaporation to remove acetonitrile, frozen in liquid nitrogen, and lyophilized to dryness. Purity was verified to be >95% using LC-MS on an Agilent QTOF 6520 LC-MS. Example chromatograms and ESI-MS spectra are shown in Supplementary Fig. S2 .
For the DSPE-PEG 2000 -AVGALEGPRNQDWLGVPRQL-COOH, purified H 2 N-AVGALEGPRNQDWLGVPRQL-COOH was dissolved in DMF along with excess diisoproplyethylamine (DIEA). This mixture was then added to approximately 2 molar equivalents of DSPE-PEG 2000 -NHS (Nanosoft Polymers) also dissolved in DMF. Reaction progress was monitored by ESI-MS until the peptide peak was consumed (approximately 18 hours) and only the polydisperse product peak, and some DSPE-PEG 2000 starting material were seen. The reaction mix was then diluted with water, and product was purified by HPLC using a Phenomenex Jupiter C12 column. After lyophilization to dryness, LCMS confirmed purity to be >95% and the product mass was a polydisperse mixture centered around 5162 m/z.
To synthesize DSPE-PEG 2000 -CAVGALEGPRNQDWLGVPRQL-COOH, purified H 2 N-CAVGALEGPRNQDWLGVPRQL-COOH was dissolved in DMF and added to approximately 1.25 molar equivalents of DSPE-PEG 2000 -maleimide (Laysan Bio) also dissolved in DMF.
Reaction progress was monitored by ESI-MS until the peptide peak was consumed (approximately 24 hours), and only the polydisperse product peak and some DSPE-PEG 2000 -maleimide were seen. The reaction mix was then diluted with water and purified as above. After 7 lyophilization to dryness, LCMS confirmed purity to be >95% and the product mass was a polydisperse mixture centered around 5349 m/z.
For synthesis of DSPE-PEG 2000 -(click)-AVGALEGPRNQDWLGVPRQL-COOH, with peptide H 2 N-AVGALEGPRNQDWLGVPRQL still on resin, 2 molar equivalents of 5-azidopentanoic acid, 1.9 molar equivalents of HBTU and 8 molar equivalents of DIEA in DMF were added. This mixture was allowed to react overnight before standard cleavage from resin and purification as described above. The purified peptide (Az)-AVGALEGPRNQDWLGVPRQL-COOH was then dissolved in DMSO along with DSPE-PEG 2000 -DBCO (Avanti) in approximately a 1:1 molar ratio. The reaction was monitored until the peptide peak was nearly consumed and the product was then purified as above. After lyophilization to dryness, LCMS confirmed purity to be >95% and the product mass was a polydisperse mixture centered around 5405 m/z.
For the ABP-antigen constructs, following synthesis of the antigen component, the PEG 2000 linker (Creative PEGworks) was coupled manually onto peptidyl resin containing the antigen peptide; the resin was then transferred back to the synthesizer to complete the construct.
The crude peptides were cleaved overnight at room temperature (by volume, 82.5% trifluoroacetic acid, 5% water, 5% thioanisole, 5% phenol, and 2.5% ethane dithiol), triturated with -80 C diethyl ether, and purified via RP-HPLC. The ABP moieties were cyclized by incubating the purified constructs (0.1 mg/mL) in 0.1 M NaHCO 3 (Sigma), pH 8.0 for 24h to facilitate disulfide formation. The cyclized constructs were desalted via solid phase extraction, lyophilized, and analyzed via LC-MS to verify identity and purity. An example chromatogram and corresponding mass spectrum is shown in Supplementary Fig. S3A For the labeled constructs, EGP long and ABP-PEG 2000 -EGP were synthesized as described above, incorporating a C-terminal propargylglycine to serve as a chemical handle.
Prior to disulfide cyclization, purified EGP long and ABP-PEG 2000 -EGP long peptides were coupled to TAMRA-azide (tetramethylrhodamine, 5-isomer, Lumiprobe) via Cu(I)-catalyzed click chemistry. Briefly, ~0.5 mol of each peptide was dissolved in 720 L of 50:50 b.v. solution of t-butanol (Sigma) and water. The following reagents were then added (final concentration in parentheses): TAMRA-azide (500 M), Tris (pH 8.0, final concentration 50 mM; Roche), ascorbic acid (100 mM, Sigma), TCEP (1 mM, Hampton Research), TBTA (100 M; Alfa Aeser), and copper sulfate (5 mM; Sigma) to a final volume of 1.00 mL. The reactions were mixed thoroughly and incubated at room temperature for one hour. The reactions were quenched in 20 mL 95:5 water: acetonitrile with 0.1% TFA additive, purified via RP-HPLC, and lyophilized. The TAMRA-labeled constructs were cyclized and desalted as described above.
Peptide antigen sequences used are as follows: gp100 EGP long, EGP 20 (gp100 [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] 
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The human HLA-B57-restricted KF11-specific CD8 + T-cell clone (recognizing KAFSPEVIPMF (20) ) was maintained in the presence of IL2 (50 U/mL, R&D Systems), using CD3-specific monoclonal antibody 12F6 (0.1 µg/mL, Enzo Life Sciences), and irradiated allogeneic feeder PBMCs.
Human peripheral blood mononuclear cells (PBMCs) were freshly isolated from HLA-B57 + blood donors with Ficoll-Hypaque (Sigma-Aldrich). PBMCs were isolated from buffy coats collected from HLA-typed blood donors after written informed consent and approval by the Partners Human Research Committee (protocol #2005P001218). Monocytes were enriched using CD14 + magnetic isolation, according to the manufacturer's instructions (EasySep™ Human Monocyte Isolation Kit, StemCell). DCs were differentiated during a 6-day culture at 10 6 cells/mL in AIM-V medium (Thermo Fisher), supplemented with 1% HEPES, 1% human AB serum, IL4 (20 ng/mL; CellGenix), and GM-CSF (10 ng/mL; CellGenix). On days 2 and 4, fresh IL4 and GM-CSF were added. DCs were harvested on day 6 and incubated with free HIV p24 28-60 peptide (VEEKAFSPEVIPMFSALSEGATPQDLNTMLNTV) or DSPE-PEG-p24 for 4 hours at 37°C and then washed. The DCs were then plated with the KF11 CD8 + T-cell clone in a 2:1 effector-to-target ratio in 96-well plates (Millipore) coated with anti-IFNγ (clone 1-D1K, Mabtech, 2 µg/mL). DCs pulsed with equivalent molar concentrations of the optimal KF11 peptide were used as controls. Cells then were cocultured overnight wrapped in foil at 37°C in AIM V medium supplemented with 1% HEPES and 10% human AB serum on human IFNγ ELISPOT plates (EMD Millipore). The ELISPOT plate was developed according to the manufacturer's protocol. Plates were scanned using a CTL-ImmunoSpot Plate Reader, and data were analyzed using CTL ImmunoSpot Software. The magnitude of the epitope-specific response was reported as the number of SFU per 10 4 T cells.
Mass spectrometry analysis of peptide degradation products
Mass spectrometry (MS) analysis of peptide fragments generated after incubation in cytosolic, endosomal, or lysosomal degradation conditions was carried out as previously described (21) . Briefly, 2 nmol of p24 peptide or DSPE-PEG-p24 were incubated with cell extracts from each cellular compartment that were isolated from antigen presenting cells derived from primary human monocytes at 37°C in 50μL of degradation buffer (50 mM TrisHCl, 1 mM MgCl 2 , 1 mM ATP, and 137 mM potassium acetate at pH 7.4, pH 5.5, or pH 4.0).
The reaction was stopped with formic acid, and peptides were purified via trichloroacetic acid precipitation. The degradation mix was injected into a Nano-HPLC ( 
Statistical analysis
Statistical methods were not used to determine sample size, but sample numbers were chosen based on estimates from pilot studies and published results, such that appropriate statistical tests may yield statistically significant results. Unless otherwise stated, analysis of tetramer and ICS results were analyzed by using one-way ANOVA with a Tukey post-test using GraphPad Prism software. Where ANOVA was used, variance between groups was found to be similar by Bartlett's test. Where comparisons were predetermined, as indicated in figure legends, ANOVA with Bonferroni correction was used. Pmel-1 proliferation data was analyzed using student's ttest within a given LN to compare EGP 20 peptide and DSPE-PEG-EGP 20 . No samples were excluded from analysis.
Results
Albumin-binding moieties enhance lymphatic drainage and immunogenicity of vaccines
We previously reported that peptide antigens conjugated to a DSPE phospholipid tail through a poly(ethylene glycol) spacer ( peptide resulted in 13.6-fold and 18.2-fold higher fluorescence in inguinal and axillary LNs 24 hours later, respectively, compared to unmodified EGP 20 (Fig. 1C-D) . Vaccination with ABP-PEG-EGP 20 elicited a 5-fold increase in antigen-specific T cells compared to unmodified peptide (Fig. 1E) .
As a second test of the generality of albumin binding as a mechanism for targeting antigen/adjuvants to LNs, we also evaluated vaccine conjugates of the most biologically active form of vitamin E, -tocopherol, which has been shown to bind to serum albumin with an affinity of K D ~7 μM (22) . Constructs utilizing vitamin E as the albumin-binding domain for EGP 20 peptide or the TLR9 agonist CpG ODN 1826 were synthesized ( Fig. 2A-B ). Fluorescence imaging of excised LNs after immunization with fluorophore-tagged Vit. E-CpG showed 2.9-fold and 3.1-fold higher CpG levels in the draining inguinal and axillary nodes, respectively, compared to unmodified oligonucleotides (Fig. 2C) . Consistent with this enhanced lymphatic delivery, mice immunized with whole protein ovalbumin (OVA) adjuvanted with Vit. E-CpG showed 10-fold higher frequencies of OVA-specific CD8 + T cells compared to vaccination with unmodified CpG or CpG conjugated with Vitamin B3, which is not known to bind to serum albumin ( Fig. 2D-E mice generated T-cell responses indistinguishable from w.t. mice ( Fig. 3A-B) .
Although amph-vaccines were found to accumulate in many APC populations in LNs, we expected that any DSPE-PEG-peptide conjugate (even optimal nonamer epitopes) may require processing to cleave the DSPE-PEG linkage for antigen presentation, and, thus, might require cross-presenting DCs for activity. To test this hypothesis, we immunized Batf3 -/-mice, which lack the transcription factor necessary to develop cross-presenting DCs (25) . Compared to w.t.
mice, priming of T-cell responses to the optimal EGP 9-mer peptide (DSPE-PEG-EGP 9 ) were severely compromised in Batf3 -/-mice ( Fig. 3C-D) , indicating that even "short" DSPE-PEGpeptides may be reliant upon cross-presenting DCs for effective priming.
Immunogenicity of amph-peptide vaccines is insensitive to conjugate linkage chemistry
We previously focused on forming amphiphile conjugates by linking DSPE-PEGmaleimide to the free thiol of an N-terminal cysteine introduced on peptide antigens. However, this conjugation chemistry would be problematic if an antigen sequence of interest had an internal cysteine. To determine whether the immunogenicity of amph-vaccines is sensitive to the linkage chemistry, conjugates were synthesized where DSPE-PEG was either linked using cysteine-maleimide chemistry, copper-free click chemistry, or via amine-succinimidyl ester chemistry to form an amide bond directly to the N-terminus of the peptide antigen ( Supplementary Fig. S1 ). All of these conjugate-peptides demonstrated superior immunogenicity relative to unmodified peptides, and conjugates formed with the different linkages were not statistically different from another (Fig. 3E) , suggesting that immunogenicity of peptide constructs is insensitive to the PEG-lipid linkage. When mice were immunized with either N-or C-terminal DSPE-PEG or ABP-PEG antigen conjugates, both showed a trend towards Nterminal conjugation being superior to C-terminal conjugation (Fig. 3F) .
Conjugation of peptide antigens with DSPE-PEG enhances serum stability
PEG conjugation has been shown to enhance the serum stability of peptides by protecting from serum proteases (12, 26) . To test whether amph-peptides show a similar increase in resistance to proteolytic degradation, unmodified EGP 20 peptide, DSPE-PEG linked to EGP 20 either through an N-terminal or C-terminal cysteine, or PEG-EGP 20 without the diacyl lipid (linked N-terminally) were incubated with fresh mouse serum. Serum-treated or fresh peptides were then added to splenocytes from gp100-primed mice, and the IFNγ production of the 
serum. By contrast, each of the PEG and DSPE-PEG peptide conjugates retained nearly maximal stimulatory activity after the same serum treatment (Fig. 4B-D) .
To evaluate the relative contribution of enhanced serum stability vs. lymphatic trafficking in the immunogenicity of amph-vaccines, mice were vaccinated with DSPE-PEG-EGP 20 (Fig. 4E) , indicating that protection from serum proteases is an important but not dominant contributing mechanism in amph-vaccine immunogenicity. Given the observation that albumin-binding conjugates both trafficked to LNs more effectively and showed enhanced stability in vivo, we directly assessed whether any dose of a soluble long peptide vaccine could elicit T-cell responses comparable to the equivalent amph-vaccine. With EGP 20 antigen, a 20x higher dose of unmodified antigen was required to elicit comparable priming (Fig. 4F) . We also carried out comparative immunizations of free peptides and amphiphile-conjugates of four additional "long" and optimal 9-mer peptide antigens, including both CD4 and CD8 epitopes, to assess the generality of the increased immunogenicity of amph-vaccines, and found consistent increases in T-cell responses elicited by each of these antigens (Supplementary Fig. S4 ). These data suggest that amph-vaccines promote an increase in vaccine potency that would be difficult to achieve in humans simply by increased free peptide dosing.
DSPE-PEG peptides achieve broad lymphatic distribution and extend in vivo presentation
Enhancement of presentation of an antigen in vivo may result from a number of distinct processes: quantitatively more peptide can be taken up in a given LN, presentation can occur in more nodes throughout the lymphatic chain, or presentation might occur for an extended duration (Fig. 5A-B) . Under these conditions, the CFSE- (Fig. 5E, F) , and presentation of DSPE-PEG-EGP 20 was seen even in the distal mesenteric nodes. Next, mice were immunized and CFSE-labeled pmel-1 T cells were transferred 7 days later. In LNs that were resected 48 hours after transfer, no proliferation in any node was seen with unmodified EGP 20 peptide, but DSPE-PEG-EGP 20 resulted in proliferation in the inguinal, axillary, and lumbar nodes, indicating that DSPE-PEG-peptide is presented for at least one week in vivo (Fig. 5G-H) . Thus, DSPE-PEG-peptides achieved broad lymphatic distribution and extended in vivo presentation.
To assess the phenotype of T cells primed by this sustained and systemic antigen presentation, we measured surface markers and cytokine production capabilities of antigen- Fig. S5A-B) . We observed that with the adjuvants used here, the CD8 + T-cell response exhibited a Tc1 rather than a Tc2 or Tc17 phenotype, as determined by production of IFNγ but not IL4 or IL17 within tetramer + CD8 + T cells (Supplementary Fig. S5C ).
Amph-peptides combine effectively with several different molecular adjuvants
Although DSPE-PEG peptides showed clear superiority over unmodified antigens when administered with molecular adjuvants, peptide vaccines are often clinically administered in combination with Incomplete Freund's Adjuvant (IFA), a water-in-oil emulsion that induces local inflammation and forms a depot, protecting antigens from degradation and releasing them over time (27) . In mouse models, peptides in IFA alone have been shown to create a sink for effector T cells, but addition of TLR agonists to peptides in IFA elicits potent immune responses and responses were quantified with ICS (Fig. 6D) . Responses to free peptides adjuvanted with either polyI:C or CDN trended towards improvement with IFA, but responses to DSPE-PEGpeptide were hindered by formulation in IFA, decreasing approximately 50% in magnitude compared to formulation in saline. These data suggest DSPE-PEG-peptides exhibit superior immunogenicity compared to unmodified peptides when combined with a number of molecular adjuvants, including the most potent clinically-employed adjuvant combinations.
Amph-peptide conjugates are processed by human APCs similarly to free peptides
To assess if processing and presentation of amph-peptides is performed efficiently by human antigen presenting cells in vitro, we performed an IFNγ ELISPOT with primary human monocyte-derived DCs. The KF11 CD8 + T-cell clone (recognizing HIV gag p24 [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] in the context of HLA-B57 (20)) was used to probe for presentation in a coculture. DCs generated from an HLA-B57 + donor were pulsed with the HIV-derived gag p24 peptide or DSPE-PEGp24 at three concentrations and cocultured with KF11-specific CD8 + T cells, and IFNγ spot forming units (SFU) were quantified. As shown in Fig. 7A , similar responses were observed for DSPE-PEG-p24 and p24 peptide, indicating that the functional integration of uptake, processing, and presentation of DSPE-PEG-peptide is equivalent to unmodified peptide in vitro for an immunodominant MHC class I restricted epitope.
The repertoire of peptides generated by antigen processing in APCs is one of many factors that influences T-cell responses (28) . To uncover if conjugation of peptide antigens with DSPE-PEG alters the cleavage patterns and resultant peptides generated, HIV gag p24 peptide or DSPE-PEG-p24 were subjected to degradation in cellular extracts from endosomal, lysosomal, or cytosolic compartments derived from human monocyte-derived DCs and analyzed by mass spectrometry as previously described (21) . The MHC class I and class II epitopes and the lengths of all fragments generated by degradation of p24 peptide and DSPE-PEG-p24 were virtually identical at both 60 and 120 minutes in each of the cellular compartments analyzed (Fig. 7B-C and Supplementary Table S1 ), suggesting that conjugation with DSPE-PEG does not interfere with antigen processing machinery by human APCs.
Discussion
We have previously shown that conjugation of CpG oligonucleotide adjuvants or peptide antigens with diacyl lipids (through a PEG spacer in the peptide case) significantly enhances LN accumulation of these vaccine agents, and, thereby, augments T-cell priming (14). Here, we extended those results to show that substitution of the diacyl lipid with -tocopherol as the albumin-binding moiety similarly enhanced both antigen and adjuvant activity. We also showed that non-lipid modifications, namely fusion of antigens with albumin-binding peptides, also allowed for enhancement of LN delivery and T-cell priming. The former result was noteworthy, given that -tocopherol has a low affinity for albumin (K D ~7 μM (22)). Effective lymphatic delivery, even with low affinity binders, is likely facilitated by the very high concentrations of albumin in interstitial fluid (29) . Our data suggest that amphiphilic peptides utilizing lipid albumin binding domains, DSPE-PEG-EGP20 and Vit. E-PEG-EGP20, are superior to compositions incorporating an ABP. However, we cannot rule out that further optimization of the affinity of these ABPs for albumin or their linkages to the peptide antigens might further increase activity of ABP-PEG-peptide conjugates (19) .
Although our prior work provided a reasonable basis for understanding how albumin could mediate vaccine trafficking, the mechanisms underlying antigen capture and processing in albondin (gp60) and several scavenger receptors that bind conformationally altered albumin to redirect it for degradation, these other receptors are not known to be expressed on antigen presenting cells (30) . Albumin is readily internalized by macropinocytosis (31) , and this may represent a main mode of uptake of albumin-bound vaccines.
Conjugation of optimal MHC I epitopes with DSPE-PEG has enhanced activity for a number of antigens (14), but it was unclear if this linkage changes the antigen presentation requirements of short peptides. Namely, short soluble peptides may undergo peptide exchange, loading directly onto MHC on the surface of non-professional antigen presenting cells, including T cells and B cells, which may promote tolerance in some circumstances (32) (33) (34) . By contrast, DSPE-PEG-peptides appear to rely on cross-presenting DCs, even for optimal nonamer antigens, which may allow optimal epitopes to be used in vaccination without concern for presentation by non-professional APCs.
The duration of antigen presentation has been shown to impact the magnitude of T cell effector and memory responses, with longer antigen presentation resulting in more effective CD8 + T cell memory formation compared to brief exposures (35, 36) , and priming in distal nodes was identified as one of the characteristics of DEC-205-targeted antigens, which promote potent CD8 + T-cell immunity (37) . Performing vaccination at multiple injection sites in order to increase the number of LNs utilized for priming has also been shown to enhance the magnitude of T-cell responses (38) . We showed here that DSPE-PEG-peptides embodied these important principles, as they are presented in multiple nodes systemically and for at least one week in vivo. We observed that with the adjuvants used here, the T-cell response exhibited a Tc1 phenotype, and we did not see evidence of exhaustion by PD-1 and Tim-3 staining. These results suggest that immunization with DSPE-PEG-peptides recapitulates some traits of systemic viral infection: presentation of antigen in many lymphoid organs for a prolonged duration.
Peptide antigen modification with PEG significantly enhanced T-cell priming, even without including an albumin-binding domain. This was likely mediated through an increase in serum stability and in vivo half-life, as has been demonstrated for PEG modification of erythropoiesis stimulating peptides and anti-viral peptides previously (12, 26) . This finding indicates that some of the activity of DSPE-PEG-peptides derives from protection of the antigen from serum proteases, although further significant enhancements in immunogenicity are seen with the addition of an albumin-binding domain.
IFA is widely used to enhance immunogenicity of unmodified peptides, but our data suggest that vaccines with lipophilic domains that rely on efficient lymphatic drainage for their mechanism of action may be hindered in activity with formulation in IFA. The mechanism of action of IFA is thought to involve extending in vivo presentation of antigen by forming an antigen depot (27) . This may be unnecessary in the case of DSPE-PEG-peptides, which showed an extended in vivo half-life. Although IFA increased priming to free peptides, IFA decreased the T-cell response approximately two-fold for DSPE-PEG-peptides, indicating that IFA should be avoided for translation of DSPE-PEG-peptides clinically. This would have the dual benefit of avoiding T-cell sequestration and induction of apoptosis in IFA depots, as has been observed in mice (10) . representative of 2 independent experiments. *P<0.05, **P<0.01, ***P<0.001. 
